Moreover, we explore the combination of CSF proteins reflecting synaptic damage such as GAP43, NRGN, SNCB and amphiphysin (AMPH) in pairs with other brain-derived proteins to evaluate their combined ability to reflect disease pathology and hence their potential to be used in clinical trials to assess the efficacy of new AD therapies. This evidence concerns the gene NRGN and Alzheimer disease.